 CAMBRIDGE, Mass., Dec. 07, 2020 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. Trillium or the Company NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology ASH Annual Meeting, taking place virtually from December 5-8, 2020, and provides guidance for 2021. 